[Changes of neurotransmitter endothelin, thromboxance B2 and 6-keto-prostaglandin F1 alpha in patients with chronic pulmonary heart disease].
OBJECTIVE
To explore the changes of the neurotransmitters in patients with chronic pulmonary heart disease (CPHD) and its clinical significance.


METHODS
Seventy-two patients with CPHD (42 males, 30 females, mean age 55.6-/+8.9 years) were enrolled in the study, including 48 patients with compensated CPHD and 24 with uncompensated CPHD. Plasma endothelin (ET), thromboxance B2 (TXB2) and 6-keto-prostaglandin F1 alpha (6-K-PGFlalpha) were detected by radioimmunoassay. Thirty blood donors were selected as the normal control.


RESULTS
Compared with the normal controls, CPHD patients showed abnormal pulmonary function, and significantly elevated levels of plasma ET and TXB2 (P<0.01) and lowered 6-K-PGFlalpha(P<0.01), but no significant differences were found between the patients with compensated CPHD and uncompensated CPHD (P>0.05). Plasma ET and TXB2 levels were inversely correlated to 6-K-PGFlalpha level (r=-0.4571, P<0.05).


CONCLUSIONS
The patients with CPHD present with obvious changes of plasma ET, TXB2 and 6-K-PGFlalpha.
Cheng
Yong
Y
Cadre Ward of Affiliated Hospital, Yan'an University, Yan'an 716000, China.
Li
Zhi-Kui
ZK
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000328:Adult; D016022:Case-Control Studies; D002908:Chronic Disease; D016232:Endothelins / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011660:Pulmonary Heart Disease / Q000097:blood*; D013929:Thromboxane B2 / Q000097:blood*
D016232:Endothelins; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha